DRREDDY

received a positive CHMP opinion from EMA for AVT03, a biosimilar of Prolia® and Xgeva®, potentially allowing marketing authorization in the EEA and UK, with commercialization rights in the U.S. and Europe under a 2024 agreement with Alvotech.